| 8 0.31 (4.03%) | 04-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.73  |
1-year : | 10.65 |
| Resists | First : | 8.33 |
Second : | 9.11 |
| Pivot price | 7.79 |
|||
| Supports | First : | 7.06 | Second : | 5.87 |
| MAs | MA(5) : | 7.98 |
MA(20) : | 7.88 |
| MA(100) : | 10.7 |
MA(250) : | 9.05 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 52.1 |
D(3) : | 58.4 |
| RSI | RSI(14): 44.3 |
|||
| 52-week | High : | 13.73 | Low : | 4.71 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NEO ] has closed below upper band by 33.4%. Bollinger Bands are 35% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.1 - 8.14 | 8.14 - 8.18 |
| Low: | 7.53 - 7.57 | 7.57 - 7.61 |
| Close: | 7.93 - 8 | 8 - 8.07 |
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Tue, 14 Apr 2026
NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Mon, 13 Apr 2026
NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026 - Business Wire
Sat, 11 Apr 2026
Tudor Investment Corp ET AL Trims NeoGenomics, Inc. $NEO Stake - National Today
Sat, 11 Apr 2026
NeoGenomics, Inc. $NEO Stake Trimmed by Tudor Investment Corp ET AL - MarketBeat
Tue, 07 Apr 2026
NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026 - Business Wire
Mon, 06 Apr 2026
NEOGENOMICS INC ($NEO) CEO 2025 Pay Revealed - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 130 (M) |
| Shares Float | 119 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 102.7 (%) |
| Shares Short | 8,370 (K) |
| Shares Short P.Month | 8,890 (K) |
| EPS | -0.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.48 |
| Profit Margin | -14.9 % |
| Operating Margin | -6.6 % |
| Return on Assets (ttm) | -3 % |
| Return on Equity (ttm) | -12.5 % |
| Qtrly Rev. Growth | 10.6 % |
| Gross Profit (p.s.) | 2.41 |
| Sales Per Share | 5.6 |
| EBITDA (p.s.) | -0.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 5 (M) |
| Levered Free Cash Flow | 17 (M) |
| PE Ratio | -9.53 |
| PEG Ratio | 0 |
| Price to Book value | 1.23 |
| Price to Sales | 1.42 |
| Price to Cash Flow | 198.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|